亚太药业：二类新药右旋酮洛芬缓释贴片II期a临床已结束，尚在评估是否开展II期b

Core Insights - The management of the company acknowledges significant changes in the pharmaceutical industry's operating environment and continues to work on improving the company's performance despite ongoing losses in its main business [1] - The company has completed Phase IIa clinical trials for its new drug, R- Ketorolac sustained-release patch, but there is uncertainty regarding the need for Phase IIb trials [1] - The company’s subsidiary, Xingya Pharmaceutical, has been sold for 175 million yuan, with the first payment of 30 million yuan already received, and the final payment expected by June 25 [1] - The company reported a decline in revenue for Q1 2025 due to weak market demand, intensified industry competition, and compressed pricing for generic drugs [1] Company Strategy - To improve operational conditions, the management plans to actively adjust the business structure, enhance promotion of high-margin products, and focus on building a strong VIP customer base [2] - The company aims to explore new uses for existing drugs to address the lack of new products in its pipeline [2] - The company is committed to launching CMO/CDMO projects, expanding into international markets, and seeking opportunities for industry consolidation to strengthen its core competitiveness [2]